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Summary The purpose of this study was to evaluate in a phase I-Il trial whether low doses of recombinant human interleukin 2 (rHuIL-2)
over a prolonged period of time are safe and effective in eradicating or controlling minimal residual disease in children with neuroblastoma
given high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). From January 1992 to July 1996, 17 consecutive
patients, with either stage IV or relapsed neuroblastoma, were enrolled. Patients received rHuIL-2 after a median time interval (min-max) of
105 days (56-153) after HDCT and ASCT. The protocol consisted of 2 'priming' courses of rHuIL-2 at escalating doses administered
intravenously at 72-h intervals, followed by 'maintenance' with 11 monthly and six bimonthly boosting 5-day courses administered
subcutaneously on an outpatient basis. At April 1997, 7 out of the 17 patients had completed the treatment schedule, four had discontinued
treatment because of toxicity and four because of relapse; the remaining two patients are still on treatment, having completed 15 courses.
Expansion of T lymphocytes, together with an increase in both natural killer cells and in activated T lymphocytes was evidenced. After a
median (min-max) follow-up time of 30 (16-64) months, 12 out of 17 patients are alive and well. Two patients relapsed and died 14 and 35
months after transplant. Three patients are alive after having relapsed at 41, 21 and 13 months. The actuarial 2-year event-free survival and
overall survival are 67% and 92% respectively. Intermittent administration of low doses of rHuIL-2 given for a long period of time is well
tolerated and seems capable of controlling minimal residual disease after HDCT and ASCT in children with high-risk neuroblastoma.
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Disseminated neuroblastoma (NB) in children over I year of age
at diagnosis remains one of the major challenges in paediatric
oncology. In the 1970s, only 10% of patients with stage IV NB
treated with conventional multimodality approaches (Hayes et al,
1989) were alive at 3 years. The introduction of intensive induc-
tion treatments followed by high-dose chemotherapy (HDCT) and
autologous stem cell transplantation (ASCT) has improved the
outcome, suppressing regrowth of neoplastic cells, but still failing
to eradicate minimal residual disease (MRD); long-term survival
is below 30% in most recent reports (Garaventa et al, 1996). In
these patients, most relapses occurred within 12 months after
transplantation, even though, in some cases, a clinical and radio-
logical complete remission (CR) had been achieved.
Experimental and clinical data demonstrate that a regenerating
immune system is functionally and structurally inadequate to
control MRD post ASCT. For 6 months or longer, transplanted
patients show an impaired immunological response and undetec-
table interleukin 2 (IL-2) serum levels (Bilgrami et al, 1994; Welte
et al, 1994).
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Addition of IL-2 to peripheral blood lymphocytes (PBL) from
patients after ASCT markedly increases the in vitro cytotoxic
activity of these cells against long-term cultured tumour targets
(Higuchi et al, 1989). After IL-2 stimulation, natural killer (NK)
cells (CD3-/CD16+, CD3-/CD56+) are the earliest lymphocytes
to reappear after ASCT. These cells show LAK activity and major
histocompatibility complex (MHC) unrestricted lysis of tumour
cells. Furthermore, IL-2 enhances the anti-tumour effect of
macrophages through induction of cytokines with antineoplastic
activity, such as a.-tumour necrosis factor (a-TNF) and y-inter-
feron (y-IFN) (Zhang et al, 1986). NB is a non-immunogenic
tumour, whose derived cell lines have been demonstrated to be
sensitive to NK lysis (Main et al, 1985). As a consequence, great
interest has arisen around the possibility that IL-2 after ASCT
could potentially lead to prolonged remission or even cure in poor-
prognosis NB (Favrot et al, 1989).
Phase I-II trials conducted on children with NB have demon-
strated that 18 x 106 U m-2 day-' represent the maximum-tolerated
dose (MTD) of IL-2 in non-grafted children (D Valteau-Couanet,
personal unpublished data) and 12 x 106 U m-2 day-' in patients
given BMT (Valteau-Couanet et al, 1995) Fever, vomiting, diar-
rhoea, hypertension, neurological symptoms together with jaun-
dice, increased serum BUN levels and weight gain were frequent
and sometimes life-threatening complications requiring discontin-
uation of treatment.
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As shown in a recent animal study addressing the use of sub-
cutaneous (s.c.) IL-2 in pigs (MJ Chiron, 1996, personal communi-
cation), it is likely that a substantial proportion of IL-2
administered s.c. distributes to the lymphoid system, where it expli-
cates its activity. Thus, subcutaneous administration may achieve a
systemic exposure similar to that obtained with i.v. administration,
but with reduced dosage. Moreover, the early phase I-II trials
postulated that rest periods between cycles could be important in
incrementing patient tolerance to treatment, improving the ability
of effector cells to respond to additional IL-2, and reducing the
increase of serum or cellular suppressive factors elicited by initial
cytokine treatment (Thompson et al, 1990).
We have evaluated whether intermittent low doses of IL-2 can
be administered without significant toxicity and whether this is
effective for adequate control of MRD potentially present after
HDCT and ASCT in children transplanted for poor-prognosis NB.
PATIENTS AND METHODS
Patients
Between January 1992 and July 1996, 17 patients who underwent
unpurged ASCT for NB either relapsed or advanced at diagnosis
were treated with rHuIL-2.
Twelve patients were male and five were female with a median
age (min-max) at diagnosis of 52 (3-96) months (Table 1).
Assessment of disease status at diagnosis and at the end of
front-line therapy was performed according to the International
Neuroblastoma Staging and Response Criteria (Brodeur et al,
1988; Brodeur et al, 1993) and included evaluation of primary
tumour, urinary catecholamine (HVA-VMA) excretion, LDH,
ferritin, bone lesions and marrow infiltration, as well as presence
ofother distant metastases. Primary tumour was studied by means
of computerized tomography (CT) scan. Evaluation of bone
disease and other sites of tumour localization was performed in
all patients with meta-iodobenzyl-guanidine (mIBG) scan. Bone
marrow (BM) aspirates were performed at two different sites
together with one or two marrow trephines.
We used Southern blot analysis to study allelic loss in the lp
chromosomal region and to determine the presence or absence
of N-mvc oncogene amplification. Cytology and immunological
phenotype were performed in all samples at onset and at different
moments during the disease course in all patients.
All patients received front-line treatment according to multi-
centre protocols, including conventional-dose multiagent chemo-
therapy and surgery; three patients were treated according to the
AIEOP NB85 protocol (Dini et al, 1991) and 14 patients according
to AIEOP NB92 front-line therapy (Donfrancesco et al, 1992).
Median interval (min-max) from diagnosis to ASCT was 9 months
(5-54). At ASCT, one patient was in third CR, one in second CR,
one in second VGPR and one in second PR after relapse, four chil-
dren were in first PR, one in first VGPR and eight in first CR. Four
patients were conditioned with fractionated total-body irradiation
(TBI) (333 cGy day-' x 3 days), vincristine (4 mg m-2 over 5 days)
and melphalan (140 mg m 2); 11 patients received busulfan
(4 mg kg-' day-' x 4 days), etoposide (800 mg m-2 day-' x 3 days)
and thiotepa (600 mg n-i2); one child received cyclophosphamide
(50 mg m-2 day-' x 4 days) and melphalan (140 mg m-2) and the
last one received cyclophosphamide (50 mg m-2 day-' x 4 days),
thiotepa (600 mg m-') and melphalan (140 mg m-'). As source of
stem cells, 15 patients received autologous marrow and two chil-
dren autologous peripheral blood stem cells (Table 1).
Pretreatment evaluation included physical examination, electro-
cardiogram (ECG), chest radiography. complete blood count,
serum chemistry, coagulative screening, serum immunoglobulins
and lymphocyte subset analysis. To fulfil eligibility criteria,
patients were required to have a good performance status (Lansky
0-1) and normal laboratory and clinical parameters of hepatic,
renal and pulmonary function. All patients were required to be free
of active infection at treatment. Patients started IL-2 when, in
absence of either disease progression or relapse, absolute
neutrophil count (ANC) was .1 x 109 1-1 and platelet (PLT) count
was >50 x 10"1-'.
Patients' parents were informed of the experimental protocol
and gave written consent.
IL-2 treatment
The treatment began at a median (min-max) interval of 105
(56-153) days after ASCT.
Recombinant human IL-2 (rHuIL-2, Proleukin, Aldesleuchina
was generously supplied by Chiron Amsterdam, The Netherlands.
The drug was 95% pure (specific activity 18 x 106 U mg-I protein)
and supplied as a lyophilized powder that was reconstituted in 95 ml
of5% glucose solution and 5 ml ofhuman albumin.
Patients were scheduled to receive initially two priming cycles
of rHuIL-2 given as a 5-day i.v. continuous infusion of 2, 4, 6, 8
and 8 x 106 U m-2 day-' separated by a 72 h interval. The initial
phase was followed by maintenance treatment consisting of 11
monthly and then six bimonthly courses administered subcuta-
neously (s.c.) for 5 days at a dosage of 2,4, 4,4 and 4 x 106 U m-2
day-, for a total of 19 courses per patient. Maintenance therapy
was administered on an outpatient basis.
Supportive care
All patients had a central venous line. During i.v. administration,
clinical surveillance consisted of monitoring (every 4 h) heart
function, respiratory rate, temperature and blood pressure.
Patients' body weight was measured once a day. Serum BUN
levels, plasma electrolytes, hepatic function, white and red blood
cells, and PLT count were monitored every 3 days. Coagulation
profile was obtained at the beginning, middle and end of each
cycle. Toxic effects were graded according to WHO criteria.
During each s.c. course, physical examination and laboratory
monitoring of haematological, hepatic, renal and coagulation
function were performed at the beginning and end of each cycle.
Thyroid function and immunoglobulin dosage were assessed
before, during and after discontinuation of rHuIL-2 therapy.
While on study, patients received prophylactic acetaminophen
every 6 h during each cycle of treatment. Prophylactic ranitidine
(5-10 mg kg-' body weight i.v.) and chlorfeniramine (I mg kg-'
body weight continuous i.v. infusion) were used during i.v. admin-
istration ofrHuIL-2 to prevent anaphylactoid reactions to the drug.
Immunological monitoring
Immunophenotypical was performed on whole blood by flow
cytometry using the following fluorescinated (FITC) and/or
phycoerythrin-conjugated (PE) monoclonal antibodies (MAb): anti-
CD56-PE (NKH-1), anti-CD16-FITC, anti-CD14-FITC, anti-HLA-
DR-PE (Becton Dickinson); anti-CD3-FITC, anti-CD25-FITC, anti-
CD4-FITC/anti-CD8-PE, anti-CD2-PE/anti-CD20-FITC (Coulter
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Immunology, Hialeah, FL). Fluorescence was analysed on an
EPICS Profile II (Coulter Electronics). The T-cell population
was identified as CD3+, CD4+ or CD8+, and NK population as
CD3-/CD16+ or CD3-/CD56+.
T-lymphocyte subsets were determined before, during and after
each i.v. course. During maintenance therapy, immunological
studies were performed before and after each cycle.
Peripheral blood (100 ,ul) was incubated for 30 min at 4'C with
each conjugated MAb and isotype-specific control MAb. Each
sample was treated with a Leukocyte Preparation System (Q-Prep,
Coulter), consisting of a matched, three-reagent system dedicated
to a specific preparation workstation to obtain erythrocyte lysis,
leucocyte stabilization and cellular membrane fixation.
Mononuclear cells (MNCs) were also evaluated for their ability
to lyse NK-sensitive (K562) tumour cell targets. MNCs were
isolated from blood using Ficoll, washed twice with phosphate-
buffered saline (PBS) and cryopreserved in 10% dimethyl
sulphoxide (DMSO). Thawed cells were maintained overnight in
24-well plates at a concentration of Ix106 cells ml-' in RPMI 1640
medium supplemented with 10% inactivated fetal calf serum, 1%
penicillin-streptomycin, 2% L-glutamine at 37°C. After overnight
resting, the effector cells were washed three times and tested
against 5'Cr-labelled targets at E:T ratios of 100:1, 30:1 and 10:1.
Four-hour chromium release cytotoxicity assays were then
performed as described by Hercend et al (1982). NK activity was
expressed as percentage ofspecific lysis of K562 target cells.
Statistical analysis
Patients' data were collected using patient-oriented report forms
filled by the responsible clinician. All information was stored,
controlled and analysed by VENUS, an integrated software system
running on an IBM mainframe at the North-East Italian
Interuniversity Computing Center (CINECA). Survival (SUR) and
event-free survival (EFS) were calculated starting from the day of
ASCT and were estimated using the Kaplan-Meier method
(Kaplan et al, 1958), as of 31 December 1996. The events consid-
ered as terminal were death, for survival, and death and either
relapse or disease progression, whichever came first, for EFS.
RESULTS
Toxicity
In one case, treatment was discontinued during the first i.v. cycle
for Gram-negative bacteraemia due to an indwelling Broviac line
colonization. Four children had treatment interrupted because of
relapse after 3, 9, 11 and 12 courses. At April 1997, all remaining
patients had completed the i.v. treatment and the 11 monthly s.c.
courses oftherapy. Three other children discontinued the treatment
during the bimonthly s.c. IL-2 phase. In these patients, drug
administration was interrupted for non-productive cough without
radiological signs or functional symptoms of pulmonary disease
(two patients) and for hepatitis C virus infection (one patient). Of
the remaining nine children, two are still in the phase ofbimonthly
rHuIL-2 administration, whereas seven have completed the
protocol. As a consequence, the overall number of i.v. and s.c.
courses of IL-2 administered to the 17 patients enrolled in the
study was 33 and 212 respectively.
Reported rHuIL-2-related toxic effects, such as fever, chills,
cutaneous rash and gastrointestinal symptoms, were easily
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levels were observed. Antithyroglobulin or antimicrosomal anti-
bodies were not found (data not shown). TSH returned to normal
levels, without any specific therapy, within 3 months from inter-
ruption ofcytokine treatment.
During rHuIL-2 i.v. administration, a decrease in circulating
PLT was observed. In detail, in five patients whose PLT count was
<75 x 109 1-1 at the beginning ofrHuIL-2 infusion, PLT decreased
to a value lower than 20 x 109 1-'. Ten platelet units were infused in
these five children. In all patients, PLT count at the end of each
cycle of maintenance phase decreased by 15-25% compared with
pretreatment values. However, none had bleeding or required PLT
transfusion.
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Figure 1 Effect of IL-2 on subset-differentiated lymphocytes. (A) Activated
T cells (CD3+/HLADR+). (B) CD4+/CD8+ lymphocytes. (C) NK cells
(CD3 -/CD56 +). Basal, median value after ASCT and before IL-2
treatment; p, median value after each cycle
managed. Fever >38'C and anorexia occurred constantly after the
third day of each i.v. course. Fever, a known side-effect related to
IL-2 administration, was easily managed using acetaminophen,
which determined a prompt disappearance ofhyperpyrexia within
a few hours after IL-2 discontinuation. Diffuse rash with mild
pruritus occurred in seven patients, while mild diarrhoea and
vomiting occurred in two patients only. Increase of ALT and AST,
reduction of albumin and coagulation factors were infrequent and
asymptomatic in all cases. No concurrent elevation in serum
bilirubin was noted. All these symptoms resolved within 24 h after
elective rHuIL-2 discontinuation.
No life-threatening toxicity was observed in our patients during
the s.c. phase. Remittent fever occurred during all s.c. courses.
Thyroid function showed asymptomatic increases of thyroid-
stimulating hormone (TSH) levels. No changes in serum thyroxin
Disease control
After a median follow-up of30 (16-64) months, five patients, one
in third CR, one in second PR, one in second VGPR, one in first
PR and one in first CR, relapsed 19, 6, 21, 13 and 41 months after
the beginning of treatment respectively. Two out of these five
patients died as a result of disease progression at 35 and 14
months.
Currently, 12 out of 17 patients are alive with no evidence of
disease (NED). Probability of2-year overall SUR (±s.e.) and EFS
(±s.e.) from ASCT is 92% (±6) and 67% (±12), respectively, for
the entire population, and 100% and 89% (±19) for the 13 patients
treated in first complete or partial response.
Haematological and immunological effects
Before starting immunotherapy, the mean number of circulating
MNC, and lymphocytes was 1.2 x l09 1-' and 0.9 x 109 l-l respec-
tively. At the end of the i.v. phase, a fourfold increment occurred
for both these cell types. This condition substantially persisted
during the maintenance phase of treatment and reached a peak at
the end of the first year of s.c. IL-2 therapy. The same pattern was
observed foreosinophil count. In a control population consisting of
children given autologous BMT for solid tumour and haematolog-
ical malignancies, mean number ofcirculating MNCs and lympho-
cytes was similar to that ofpatients before start ofimmunotherapy.
However, in the controls, spontaneous increase in the number of
circulating MNCs and lymphocytes of the magnitude observed in
the study population was never recorded (data not shown). No
changes were observed in the number ofcirculating neutrophils or
monocytes during either i.v. infusion or s.c. administration.
Analysis of lymphocyte subpopulations by immunopheno-
typing revealed a three- to fivefold increase in activated T cells
(CD3+/DR+) during the i.v. and s.c. treatment phases (Figure IA).
All patients responded to rHuIL-2, with an increase in the expres-
sion ofCD25. This increase was maximum during the i.v. phase, at
the end of which an increment of at least 15-fold in CD25+ cells
was observed (data not shown).
Increase in the absolute number of CD4+ and CD8+ cells was
observed in all cases. In particular, the CD4+/CD8+ ratio regularly
increased during treatment from 0.7 to 2.5 within the first year
after ASCT (Figure IB).
CD56+ cells markedly increased during the i.v. phase of
therapy, with a median 16-fold increment. These cells remained
constantly higher (1.5- to twofold) compared with basal levels
during the first year of treatment (Figure IC). A similar response
pattern was observed in the CD16+ NK subset.
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B lymphocyte and serum immunoglobulin levels did not show
significant modifications.
As far as the capacity of NK cells to lyse the sensitive K562
tumour cell line is concerned, increases in the degree ofcytoxicity
and percentage of lysis of three (E:T ratio 100:1), six (E:T ratio
30:1) and 20 (E:T ratio 10:1)-fold were evident in the patients
tested (data not shown).
DISCUSSION
Antineoplastic activity of IL-2 has been demonstrated in solid
tumours and could play a potential role in the prevention ofrelapse
and progression ofdisease.
NB cells, in vivo, do not express either class I or class II MHC
antigens, and, in vitro, NB cell lines have been shown to be sensi-
tive to NK MHC-unrestricted lysis but not to T-cell-mediated lysis
(Main et al, 1985; Main et al, 1988). In vivo, administration of
high-dose IL-2 has been shown to increase both the number and
the function activity of NK cells after ASCT (Marti et al, 1995).
The authors hypothesized that in vivo expansion of the number of
NK cells can contribute to prolong the maintenance of a state of
haematological remission. However, previously published results
have demonstrated that, in children given BMT for NB, IL-2 treat-
ment produced relevant side-effects (Negrier et al, 1991). In
particular. Negrier et al (1991) documented, in patients with
advanced metastatic NB, that a dosage of IL-2 of 18 x 106 U m-2
was extremely toxic (two toxic deaths), making it very difficult
and often impossible to administer prolonged or repeated courses
oftherapy.
Our study was designed to determine whether lower doses of
IL-2, administered early after HDCT and ASCT over a prolonged
time, might improve the outcome of poor-prognosis NB, and
produce an immune-mediated anti-tumour effect, without any life-
threatening toxicity.
All patients but one completed the i.v. priming phase. The only
child requiring discontinuation ofi.v. administration had a concomi-
tant Gram-negative sepsis, which made it difficult to attribute the
observed toxicity to rHuIL-2. The remaining patients did not
develop either hypotension, pulmonary capillary leak syndrome or
increased serum BUN levels. Only 3 out of 16 patients required
interruption of s.c. therapy because oflate side-effects. Neither early
nor delayed increase in infections was registered as a consequence
of therapy. Despite prolonged therapy and high cumulative dose of
IL-2 administered, no thyroid dysfunction was observed and none of
the patients developed thyroid autoantibodies.
Many authors describe thrombocytopenia as one of the most
frequent side-effects of high-dose IL-2 treatment, even in patients
who had normal PLT values at the beginning of IL-2 treatment. In
some cases, thrombocytopenia was reported to be severe, with
values lower than 30 x 1091-', and causing haemorrhagic death in at
least one case (Paciucci et al, 1990). Guarini et al (1991) have
demonstrated that thrombocytopenia during high-dose IL-2 treat-
ment is likely to be largely attributed to the cytolytic effect ofIL-2-
generated LAK cells on bone marrow megakaryocytic progenitors.
In our experience, severe thrombocytopenia was observed only in
patients with PLT count lower than 75 x 109 1-' at the beginning of
IL-2 therapy during the i.v. phase. No bleeding episodes occurred.
Thrombocytopenia occurring during the early phase of haemato-
logical recovery after HDCT may contraindicate an early start of
IL-2 administration. However, in our protocol, thrombocytopenia
was never associated with any clinically relevant bleeding and,
thus, it does not seem to represent a major limitation to starting IL-
2 therapy early after ASCT. Moreover, in the future, the increasing
use ofperipheral blood stem cells for ASCT should permit an even
earlier inception ofcytokine treatment.
Because of the overall mild toxicity, the patients' compliance to
the treatment schedule was high; in addition the s.c. treatment
could be administered on an outpatient basis in all cases.
Therefore, our treatment schedule resulted both in a good quality
of life and in a reduction of costs.
Patients enrolled in our study had a probability of remaining in
remission at 2 years of about 70%. Notwithstanding the fact that
almost half of the patients had an observation time ofonly 2 years,
it is noteworthy that this value compares favourably with previ-
ously published results obtained in children with high-risk NB
given BMT (Seeger et al, 1991; Garaventa et al, 1996). Even
though these data have been obtained in a prospective non-random-
ized study enrolling a limited number of patients, treatment with
immunotherapy seems, at least, to be able to delay both disease
recurrence and progression, after intensive chemoradiotherapy.
Ladenstein et al (1994) documented that mIBG positiveness at
time of transplantation predicted for a poor outcome. Thus, as a
further note of caution in the interpretation of our results, we can
not exclude that mIBG negativity at transplantation in 12 of 17 of
our patients might have partly contributed to the favourable
outcome.
The low incidence of N-mvc amplification at diagnosis could
also explain the good results observed in our cohort of patients.
In conclusion, this study demonstrates the safety and feasibility
of prolonged immunotherapy with intermittent low doses of IL-2
and suggests some further considerations. Even though the
priming i.v. phase has been reported to be important in stimulating
immunological activation and, in particular, the expansion of the
NK population (Pardo et al, 1996), it is potentially responsible for
the major toxic effects. Moreover, this phase requires hospitaliza-
tion for careful monitoring, resulting in both an increment of costs
and worsening of the patients' quality of life. Therefore, in future
studies, the importance of maintaining the priming phase should
be questioned.
The second year of treatment does not appear to be effective in
controlling MRD, possibly as a consequence of the inability of a
bimonthly schedule to enhance the anti-tumour immune mechanisms.
An early recovery from immunosuppression after HDCT and
ASCT may contribute to improved EFS in these patients. The IL-
2-mediated immunological effect directed towards malignant cells
is probably more effective in controlling conditions characterized
by a limited tumour burden. This speculation, together with the
disappointing results obtained in patients with overt relapse after
BMT, suggests that IL-2 treatment should be started as soon as
possible after HDCT.
A prospective randomized phase III clinical trial comparing
post-ASCT immunotherapy with no additional treatment is needed
to evaluate, in a controlled study, the real efficacy of intermittent
low-dose s.c. IL-2 after ASCT in poor-prognosis NB. Further
studies are also required to elucidate the mechanisms triggered by
IL-2 that can contribute to the suppression or to the eradication of
malignant cells escaping high-dose chemoradiotherapy.
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